Ferreira Juliano, Beirith Alessandra, Mori Marcelo A S, Araújo Ronaldo C, Bader Michael, Pesquero João B, Calixto João B
Department of Pharmacology, Centre of Biological Sciences, Universidade Federal de Santa Catarina, 88015-420 Florianópolis, Brazil.
J Neurosci. 2005 Mar 2;25(9):2405-12. doi: 10.1523/JNEUROSCI.2466-04.2005.
Injury to peripheral nerves often results in a persistent neuropathic pain condition that is characterized by spontaneous pain, allodynia, and hyperalgesia. Nerve injury is accompanied by a local inflammatory reaction in which nerve-associated and immune cells release several pronociceptive mediators. Kinin B1 receptors are rarely expressed in nontraumatized tissues, but they can be expressed after tissue injury. Because B1 receptors mediate chronic inflammatory painful processes, we studied their participation in neuropathic pain using receptor gene-deleted mice. In the absence of neuropathy, we found no difference in the paw-withdrawal responses to thermal or mechanical stimulation between B1 receptor knock-out mice and 129/J wild-type mice. Partial ligation of the sciatic nerve in the wild-type mouse produced a profound and long-lasting decrease in thermal and mechanical thresholds in the paw ipsilateral to nerve lesion. Threshold changed neither in the sham-operated animals nor in the paw contralateral to lesion. Ablation of the gene for the B1 receptor resulted in a significant reduction in early stages of mechanical allodynia and thermal hyperalgesia. Furthermore, systemic treatment with the B1 selective receptor antagonist des-Arg9-[Leu8]-bradykinin reduced the established mechanical allodynia observed 7-28 d after nerve lesion in wild-type mice. Partial sciatic nerve ligation induced an upregulation in B1 receptor mRNA in ipsilateral paw, sciatic nerve, and spinal cord of wild-type mice. Together, kinin B1 receptor activation seems to be essential to neuropathic pain development, suggesting that an oral-selective B1 receptor antagonist might have therapeutic potential in the management of chronic pain.
外周神经损伤常导致持续性神经病理性疼痛状态,其特征为自发性疼痛、痛觉过敏和痛觉超敏。神经损伤伴随着局部炎症反应,其中与神经相关的细胞和免疫细胞会释放多种伤害性感受介质。缓激肽B1受体在未受损伤的组织中很少表达,但在组织损伤后可表达。由于B1受体介导慢性炎症性疼痛过程,我们使用受体基因敲除小鼠研究了它们在神经病理性疼痛中的作用。在没有神经病变的情况下,我们发现B1受体敲除小鼠和129/J野生型小鼠对热刺激或机械刺激的爪部退缩反应没有差异。野生型小鼠坐骨神经部分结扎导致神经损伤同侧爪部的热阈值和机械阈值显著且持久降低。假手术动物以及损伤对侧爪部的阈值均未改变。B1受体基因的缺失导致机械性痛觉过敏和热痛觉超敏早期阶段显著减轻。此外,用B1选择性受体拮抗剂去-Arg9-[Leu8]-缓激肽进行全身治疗可减轻野生型小鼠神经损伤后7 - 28天观察到的已确立的机械性痛觉过敏。坐骨神经部分结扎诱导野生型小鼠同侧爪部、坐骨神经和脊髓中B1受体mRNA上调。总之,缓激肽B1受体激活似乎对神经病理性疼痛的发展至关重要,这表明口服选择性B1受体拮抗剂在慢性疼痛管理中可能具有治疗潜力。